Cargando…

Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure

AIMS: Cardiac mortality in patients with heart failure (HF) is likely to be aggravated by malnutrition, assessed by serum cholinesterase (ChE) level, as well as by kidney dysfunction or impairment of cardiac sympathetic denervation. Their prognostic interactions, however, have not been determined. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Takahiro, Nakata, Tomoaki, Tsuzuki, Taro, Mita, Tomohiro, Nagahara, Daigo, Yuda, Satoshi, Hashimoto, Akiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570798/
https://www.ncbi.nlm.nih.gov/pubmed/37840949
http://dx.doi.org/10.3389/fcvm.2023.1131282
_version_ 1785119850386948096
author Doi, Takahiro
Nakata, Tomoaki
Tsuzuki, Taro
Mita, Tomohiro
Nagahara, Daigo
Yuda, Satoshi
Hashimoto, Akiyoshi
author_facet Doi, Takahiro
Nakata, Tomoaki
Tsuzuki, Taro
Mita, Tomohiro
Nagahara, Daigo
Yuda, Satoshi
Hashimoto, Akiyoshi
author_sort Doi, Takahiro
collection PubMed
description AIMS: Cardiac mortality in patients with heart failure (HF) is likely to be aggravated by malnutrition, assessed by serum cholinesterase (ChE) level, as well as by kidney dysfunction or impairment of cardiac sympathetic denervation. Their prognostic interactions, however, have not been determined. METHODS: A total of 991 systolic HF patients were enrolled in our HF database following clinical evaluation including evaluation of the nutrition state and assessment of standardized heart-to-mediastinum ratio (sHMR) of iodine-123-labeled meta-iodobenzylguanidine activity. Patients were followed up for an average of 43 months with the primary endpoint of fatal cardiac events (CEs). RESULTS: The CE patient group had a lower level of ChE, lower estimated glomerular filtration rate (eGFR) and lower late sHMR than those in the non-CE patient group. A five-parameter model with the addition of serum ChE selected in the multivariate logistic analysis (model 2) significantly increased the AUC predicting risk of cardiac events compared with a four-parameter model without serum ChE (model 1), and net reclassification analysis also suggested that the model with the addition of serum cholinesterase significantly improved cardiac event prediction. Moreover, in overall multivariate Cox hazard analysis, serum ChE, eGFR and late sHMR were identified to be significant prognostic determinants. HF patients with two or all of the prognostic variables of serum ChE < 230 U/L, eGFR < 48.8 ml/min/1.73 m(2) and late sHMR < 1.90 had significantly and incrementally increased CE rates compared to those in HF patients with none or only one of the prognostic variables. CONCLUSION: Decreases in cholinesterase level and kidney function further increase cardiac mortality risk in HF patients with impairment of cardiac sympathetic innervation.
format Online
Article
Text
id pubmed-10570798
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105707982023-10-14 Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure Doi, Takahiro Nakata, Tomoaki Tsuzuki, Taro Mita, Tomohiro Nagahara, Daigo Yuda, Satoshi Hashimoto, Akiyoshi Front Cardiovasc Med Cardiovascular Medicine AIMS: Cardiac mortality in patients with heart failure (HF) is likely to be aggravated by malnutrition, assessed by serum cholinesterase (ChE) level, as well as by kidney dysfunction or impairment of cardiac sympathetic denervation. Their prognostic interactions, however, have not been determined. METHODS: A total of 991 systolic HF patients were enrolled in our HF database following clinical evaluation including evaluation of the nutrition state and assessment of standardized heart-to-mediastinum ratio (sHMR) of iodine-123-labeled meta-iodobenzylguanidine activity. Patients were followed up for an average of 43 months with the primary endpoint of fatal cardiac events (CEs). RESULTS: The CE patient group had a lower level of ChE, lower estimated glomerular filtration rate (eGFR) and lower late sHMR than those in the non-CE patient group. A five-parameter model with the addition of serum ChE selected in the multivariate logistic analysis (model 2) significantly increased the AUC predicting risk of cardiac events compared with a four-parameter model without serum ChE (model 1), and net reclassification analysis also suggested that the model with the addition of serum cholinesterase significantly improved cardiac event prediction. Moreover, in overall multivariate Cox hazard analysis, serum ChE, eGFR and late sHMR were identified to be significant prognostic determinants. HF patients with two or all of the prognostic variables of serum ChE < 230 U/L, eGFR < 48.8 ml/min/1.73 m(2) and late sHMR < 1.90 had significantly and incrementally increased CE rates compared to those in HF patients with none or only one of the prognostic variables. CONCLUSION: Decreases in cholinesterase level and kidney function further increase cardiac mortality risk in HF patients with impairment of cardiac sympathetic innervation. Frontiers Media S.A. 2023-09-29 /pmc/articles/PMC10570798/ /pubmed/37840949 http://dx.doi.org/10.3389/fcvm.2023.1131282 Text en © 2023 Doi, Nakata, Tsuzuki, Mita, Nagahara, Yuda and Hashimoto. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Doi, Takahiro
Nakata, Tomoaki
Tsuzuki, Taro
Mita, Tomohiro
Nagahara, Daigo
Yuda, Satoshi
Hashimoto, Akiyoshi
Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
title Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
title_full Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
title_fullStr Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
title_full_unstemmed Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
title_short Decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
title_sort decreased cholinesterase level combined with renal dysfunction and sympathetic denervation associated with increased cardiac mortality in systolic heart failure
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570798/
https://www.ncbi.nlm.nih.gov/pubmed/37840949
http://dx.doi.org/10.3389/fcvm.2023.1131282
work_keys_str_mv AT doitakahiro decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure
AT nakatatomoaki decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure
AT tsuzukitaro decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure
AT mitatomohiro decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure
AT nagaharadaigo decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure
AT yudasatoshi decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure
AT hashimotoakiyoshi decreasedcholinesteraselevelcombinedwithrenaldysfunctionandsympatheticdenervationassociatedwithincreasedcardiacmortalityinsystolicheartfailure